Literature DB >> 20566826

Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis.

Ying Yuan1, Xiao-Song Chen, Shi-Yuan Liu, Kun-Wei Shen.   

Abstract

OBJECTIVE: Prediction of pathologic complete remission in breast cancer after preoperative therapy presents difficulties. We performed a meta-analysis to determine the ability of MRI to predict pathologic complete remission in patients with breast cancer after preoperative therapy.
MATERIALS AND METHODS: Medical subject heading terms ("MRI" and "Breast Neoplasm") and key words ("neoadjuvant" or "primary systemic" or "preoperative" or "presurgery") were used for a literature search in the MEDLINE database. A meta-analysis of pooled data from eligible studies was performed to estimate the accuracy of MRI in predicting pathologic complete remission after preoperative therapy in patients with breast cancer.
RESULTS: Twenty-five studies were included in this meta-analysis. Pooled weighted estimates of sensitivity and specificity were 0.63 (range, 0.56-0.70) and 0.91 (range, 90.89-0.92), respectively. Heterogeneity between studies was highly influenced by the pathologic complete remission rate, with a regression coefficient of -6.160 (p = 0.020). Subgroup analysis showed that the specificity of MRI in studies with a pathologic complete remission rate of > or = 20% was lower than that in studies with a pathologic complete remission rate of < 20% (p = 0.0003).
CONCLUSION: This meta-analysis indicates that MRI has high specificity and relatively lower sensitivity in predicting pathologic complete remission after preoperative therapy in patients with breast cancer. The pathologic complete remission rate may influence the performance of MRI accuracy in this setting, which deserves further investigation.

Entities:  

Mesh:

Year:  2010        PMID: 20566826     DOI: 10.2214/AJR.09.3908

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  31 in total

1.  Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.

Authors:  Daniel I Golden; Jafi A Lipson; Melinda L Telli; James M Ford; Daniel L Rubin
Journal:  J Am Med Inform Assoc       Date:  2013-06-19       Impact factor: 4.497

Review 2.  Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review.

Authors:  R Prevos; M L Smidt; V C G Tjan-Heijnen; M van Goethem; R G Beets-Tan; J E Wildberger; M B I Lobbes
Journal:  Eur Radiol       Date:  2012-09-16       Impact factor: 5.315

3.  FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.

Authors:  Sara Sheikhbahaei; Tyler J Trahan; Jennifer Xiao; Mehdi Taghipour; Esther Mena; Roisin M Connolly; Rathan M Subramaniam
Journal:  Oncologist       Date:  2016-07-08

4.  Automated breast volume scanner (ABVS) compared to handheld ultrasound (HHUS) and contrast-enhanced magnetic resonance imaging (CE-MRI) in the early assessment of breast cancer during neoadjuvant chemotherapy: an emerging role to monitoring tumor response?

Authors:  Anna D'Angelo; Armando Orlandi; Enida Bufi; Sara Mercogliano; Paolo Belli; Riccardo Manfredi
Journal:  Radiol Med       Date:  2021-01-01       Impact factor: 3.469

5.  Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

Authors:  Bradon R McDonald; Tania Contente-Cuomo; Stephen-John Sammut; Ahuva Odenheimer-Bergman; Brenda Ernst; Nieves Perdigones; Suet-Feung Chin; Maria Farooq; Rosa Mejia; Patricia A Cronin; Karen S Anderson; Heidi E Kosiorek; Donald W Northfelt; Ann E McCullough; Bhavika K Patel; Jeffrey N Weitzel; Thomas P Slavin; Carlos Caldas; Barbara A Pockaj; Muhammed Murtaza
Journal:  Sci Transl Med       Date:  2019-08-07       Impact factor: 17.956

6.  Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?

Authors:  Maxine S Jochelson; Katharine Lampen-Sachar; Girard Gibbons; Chau Dang; Diana Lake; Elizabeth A Morris; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2015-03-17       Impact factor: 5.344

7.  Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.

Authors:  Kenneth E Pengel; Bas B Koolen; Claudette E Loo; Wouter V Vogel; Jelle Wesseling; Esther H Lips; Emiel J Th Rutgers; Renato A Valdés Olmos; Marie Jeanne T F D Vrancken Peeters; Sjoerd Rodenhuis; Kenneth G A Gilhuijs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-29       Impact factor: 9.236

8.  Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer.

Authors:  Manuela Durando; Lucas Gennaro; Gene Y Cho; Dilip D Giri; Merlin M Gnanasigamani; Sujata Patil; Elizabeth J Sutton; Joseph O Deasy; Elizabeth A Morris; Sunitha B Thakur
Journal:  Eur J Radiol       Date:  2016-06-28       Impact factor: 3.528

9.  Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.

Authors:  Soo-Yeon Kim; Nariya Cho; Sung Ui Shin; Han-Byoel Lee; Wonshik Han; In Ae Park; Bo Ra Kwon; Soo Yeon Kim; Su Hyun Lee; Jung Min Chang; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2018-01-29       Impact factor: 5.315

10.  Avoiding breast cancer surgery in a select cohort of complete responders to neoadjuvant chemotherapy: The long-term outcomes.

Authors:  Anuradha Apte; Simon Marsh; Sankaran Chandrasekharan; Arunmoy Chakravorty
Journal:  Ann Med Surg (Lond)       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.